<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27873094</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>09</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1435-5922</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>52</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of gastroenterology</Title>
                <ISOAbbreviation>J. Gastroenterol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>520-533</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00535-016-1285-y</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Elbasvir (EBR) in combination with grazoprevir (GZR) has demonstrated efficacy in patients with hepatitis C virus (HCV) infections in trials primarily conducted in the USA and Europe. We investigated the safety and efficacy of EBR in combination with GZR in Japanese patients with chronic HCV infection, with or without cirrhosis.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The study was conducted in two parts. In part 1, noncirrhotic patients were randomized 1:1 to receive EBR (50 mg) in combination with GZR (50 or 100 mg) once daily for 12 weeks. In part 2, noncirrhotic patients were randomized 3:1 to receive immediate or deferred treatment with EBR (50 mg) and GZR (100 mg, determined in part 1) for 12 weeks; cirrhotic patients received open-label immediate treatment. The primary efficacy end point was the rate of sustained virologic response 12 weeks after completion of the study treatment.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In part 1, 63 patients were randomized to receive EBR in combination with GZR at a dose of 50 mg (n = 31) or 100 mg (n = 32). The SVR12 rates were 100% with GZR at a dose of 50 mg and 96.8% with GZR at a dose of 100 mg. Tolerability was similar in both arms. In part 2, 301 noncirrhotic patients were randomized to receive immediate treatment (n = 227) or deferred treatment (n = 74), and 35 cirrhotic patients were enrolled. The SVR12 rates were 96.5% and 97.1% after immediate treatment in noncirrhotic and cirrhotic patients respectively. Safety was generally similar between immediate and deferred treatment.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Treatment with EBR in combination with GZR for 12 weeks is effective and well tolerated in Japanese patients with chronic HCV infection. CLINICALTRIALS.</AbstractText>
                <AbstractText Label="GOV IDENTIFIER" NlmCategory="UNASSIGNED">NCT02203149.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kumada</LastName>
                    <ForeName>Hiromitsu</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Toranomon Hospital, 1-3-1 Kajigaya, Takatsu-ku, Kawasaki, Kanagawa, 213-8587, Japan. kumahiro@toranomon.gr.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Suzuki</LastName>
                    <ForeName>Yoshiyuki</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Toranomon Hospital, 1-3-1 Kajigaya, Takatsu-ku, Kawasaki, Kanagawa, 213-8587, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karino</LastName>
                    <ForeName>Yoshiyasu</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Sapporo Kosei General Hospital, North-3 East-8, Chuou-ku, Sapporo, Hokkaido, 060-0033, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chayama</LastName>
                    <ForeName>Kazuaki</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawada</LastName>
                    <ForeName>Norifumi</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Okanoue</LastName>
                    <ForeName>Takeshi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, 1-2 Kawazono-cho, Suita-Shi, Osaka, 564-0013, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Itoh</LastName>
                    <ForeName>Yoshito</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mochida</LastName>
                    <ForeName>Satoshi</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Saitama Medical University, 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Toyoda</LastName>
                    <ForeName>Hidenori</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Ogaki Municipal Hospital, 4-86 Minaminokawa, Ogaki, 503-8502, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoshiji</LastName>
                    <ForeName>Hitoshi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Third Department of Internal Medicine, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takaki</LastName>
                    <ForeName>Shintaro</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology/Liver Center, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, 1-9-6, Senda-machi, Naka-ku, Hiroshima, 730-8619, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yatsuzuka</LastName>
                    <ForeName>Naoyoshi</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>MSD K.K., 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, 102-8667, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yodoya</LastName>
                    <ForeName>Etsuo</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>MSD K.K., 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, 102-8667, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iwasa</LastName>
                    <ForeName>Takashi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>MSD K.K., 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, 102-8667, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fujimoto</LastName>
                    <ForeName>Go</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>MSD K.K., 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, 102-8667, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robertson</LastName>
                    <ForeName>Michael N</ForeName>
                    <Initials>MN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co.Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Black</LastName>
                    <ForeName>Stuart</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co.Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caro</LastName>
                    <ForeName>Luzelena</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co.Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wahl</LastName>
                    <ForeName>Janice</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co.Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02203149</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>J Gastroenterol</MedlineTA>
            <NlmUniqueID>9430794</NlmUniqueID>
            <ISSNLinking>0944-1174</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000589335">2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8YE81R1X1J</RegistryNumber>
                <NameOfSubstance UI="C578009">MK-5172</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Clinical trial</Keyword>
            <Keyword MajorTopicYN="N">Efficacy</Keyword>
            <Keyword MajorTopicYN="N">Genotype</Keyword>
            <Keyword MajorTopicYN="N">Sustained virologic response</Keyword>
            <Keyword MajorTopicYN="N">Therapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>08</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27873094</ArticleId>
            <ArticleId IdType="doi">10.1007/s00535-016-1285-y</ArticleId>
            <ArticleId IdType="pii">10.1007/s00535-016-1285-y</ArticleId>
            <ArticleId IdType="pmc">PMC5357479</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Infect Dis. 2016 Jan 1;62(1):32-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26371152</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet HIV. 2015 Aug;2(8):e319-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26423374</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatol Res. 2016 Feb;46(2):129-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26876581</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2015 Jul 7;163(1):1-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25909356</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2015 Jun;15(6):645-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25863559</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>ChemMedChem. 2013 Dec;8(12):1930-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24127258</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gastroenterol. 2016 Jan;51(1):63-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25904097</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2015 Mar 21;385(9973):1087-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25467560</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Intervirology. 2010;53(1):39-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20068339</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2014 Jun;59(6):2083-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24604476</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2015 Sep;63(3):564-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25895428</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2014 Aug;147(2):366-76.e6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24727022</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Microbiol Infect. 2011 Feb;17(2):107-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21091831</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22615282</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2015 Mar 21;385(9973):1075-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25467591</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2014 Nov;61(1 Suppl):S45-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25086286</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncology. 2002;62 Suppl 1:8-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11868791</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Oct;62(4):1037-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26147154</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2015 Oct 17;386(10003):1537-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26456905</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>